Genflow Biosciences PLC (LON: GENF) has reported encouraging preliminary interim results from its SLAB clinical trial assessing its SIRT6 gene therapy in aged dogs.
Genflow Biosciences Plc appointed Gad Berdugo as Independent Non-Executive Chairman
Genflow Biosciences Plc (LON: GENF) has appointed Gad Berdugo as Independent Non-Executive Chairman, a move intended to support the group’s next phase of corporate development and R&D expansion.
Genflow Biosciences PLC (LON: GENF) A Review of an Exciting 2025
Genflow Biosciences PLC (LON: GENF) said it made solid operational progress during 2025, advancing multiple programmes across aging, metabolic disease and gene therapy, while laying the groundwork for a more
Genflow Biosciences Plc (LON: GENF) Completion of Dosing Phase of Canine Gene Therapy
Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration
Genflow Biosciences Plc (LON: GENF) to pitch longevity gene therapy at JPM 2026
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference
Genflow Biosciences Shares Jump 25% on Positive Dog Aging Gene Therapy Results
Update on Animal Health Program
Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement
Genflow Biosciences Raises £440,000 Through Alternative Share Placement.
Genflow Biosciences (LON: GENF) Files Patent Examination Request in China for SIRT6 Variants in NASH
Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis
Genflow Biosciences Advances Toward Human Trials for Ageing Therapies
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
Genflow Biosciences (LON:GENF) Advancements in SIRT6 Variant Patent Application
Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office
Genflow Biosciences implements internal modifications to better align with its objectives in the US
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
Genflow Biosciences – Intention to Float on the London Stock Exchange
Genflow Biosciences Plc (“Genflow” or ” the Company”), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of ageing and diseases associated with